What did @joeknowsthings2 actually say?
The creator laid out a week-by-week timeline for subcutaneous NAD+ injections, starting at what they described as a fixed dose given two to three times per week. They promised a progression from mental clarity and fewer energy crashes in weeks one to two, through steadier energy and better sleep by weeks three to four, all the way to "cellular energy production" and faster training recovery by weeks five to six. They also called NAD+ "one of the safest compounds to run long term" and pointed viewers toward a paid course for dosing guidance.
A few specific claims deserve attention: that most people tolerate the starting point immediately with no gradual ramp needed, that flushing during injection is manageable with slow administration, and that the compound supports "DNA repair, mitochondrial health, and long term cellular function" quietly in the background. The creator also said that for "longevity or anti-aging goals, this is where repair processes are fully active" by week five or six.
Does the science back this up?
Partially, but the confidence level here runs well ahead of the actual evidence. NAD+ precursor research is genuinely interesting, but most human clinical data comes from oral precursors like NMN or NR, not subcutaneous NAD+.
What we do know: NAD+ levels decline with age, and replenishing them in animal models produces real metabolic and neuroprotective effects (Yoshino et al., 2018, Cell Metabolism). Human trials using oral NMN showed modest improvements in muscle insulin sensitivity in older women (Yoshino et al., 2021, Science). Subcutaneous NAD+ specifically has almost no published human RCT data. The flushing mechanism the creator mentions is real and tied to prostaglandin release, and slower injection does reduce it, so that practical note is accurate. However, the precise week-by-week progression the creator describes has no clinical trial backing it. That timeline is anecdotal scaffolding presented as if it were a pharmacokinetic fact.
What did they get wrong (or right)?
Credit where it is due: the biology underlying NAD+ is legitimate. NAD+ is a coenzyme involved in mitochondrial function and is a substrate for sirtuins and PARP enzymes that participate in DNA repair (Cantó et al., 2015, Cell Metabolism). Saying it supports "mitochondrial health" is not wrong in principle.
What is wrong, or at least oversold:
- The claim that "repair processes are fully active" by week five to six implies a clinical certainty that does not exist in the published literature for subcutaneous administration.
- Calling it "one of the safest compounds to run long term" is not supported by long-term human safety data for injectable NAD+. Safety profiles from NR and NMN oral studies extend to a few months at most (Martens et al., 2020, Nature Communications).
- The structured weekly timeline reads like clinical protocol. It is not. It is a narrative built from anecdote, and presenting it this way to 31,700 viewers is misleading.
- Directing people to a paid course for dosing and reconstitution crosses a line. Dosing guidance for injectable compounds belongs in a clinical context, not a TikTok bio link.
What should you actually know?
NAD+ research is a legitimate and active area of study, but the injectable subcutaneous route has almost no peer-reviewed human safety or efficacy data independent of the IV administration literature. If you are interested in NAD+ support, the honest answer is that oral precursors like NMN and NR have more published human data behind them, even if that data is still early and modest.
The flushing and warmth the creator mentions are real adverse effects, and they are not always trivial. Some people experience nausea, headache, and significant discomfort, particularly at higher amounts. Anyone considering injectable NAD+ should be doing so under physician supervision with proper lab monitoring, not following a week-by-week social media script.
Long-term safety of subcutaneous NAD+ in humans is genuinely unknown. "Quiet background support" is a reassuring phrase, but it is not a toxicology profile. A regulated telehealth provider can help you evaluate whether NAD+ precursor therapy is appropriate for your specific situation and monitor for any issues that arise.